News Releases

Summary ToggleEDISON, N.J. , Oct. 19, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it has dosed its first patient in the IND opening, Phase 1 study of tenofovir

Summary ToggleCollaboration Aimed Towards Reaching a Cure for Hepatitis B Virus (HBV) Infection EDISON, N.J. , Oct. 17, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today

Summary ToggleEDISON, N.J. , Oct. 12, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will participate in an analyst day event sponsored by the Liver Institute

Summary ToggleEDISON, N.J. , Oct. 03, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will be featured as a presenting company at The MicroCap Conference , held

Summary ToggleEDISON, N.J. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will be featured at a symposium discussion titled “Targeting HBV.” Robert

Summary ToggleEDISON, N.J. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the U.S. Food and Drug Administration ( FDA ) has approved an

Summary ToggleEDISON, N.J. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the Clinical Trial Application (CTA) for the formulation optimization

Summary ToggleEDISON, N.J. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will be featured as a presenting company at the 19 th Annual Rodman &

Summary ToggleEDISON, N.J. , Aug. 21, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the United States Patent and Trademark Office (USPTO) has issued a new

Summary ToggleEDISON, N.J. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today an abstract for TXL™ has been selected by the Scientific Program Committee of